ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MSLE / options
RNA (44) MENS (33) DERM (16) NBP (34) ⌘ Pro Terminal →

Satellos Bioscience Inc. (MSLE) Options Positioning, Max Pain & Unusual Sweeps

$6.40 -4.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.34

Satellos Bioscience Inc. (MSLE) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $142.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MSLE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MSLE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Satellos Bioscience Inc. (NASDAQ: MSLE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $6.40 (-4.48% 1D, market cap $142.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MSLE ranks #337 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MSLE compare to RNA and MENS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MSLE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNA (Atrium Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, MSLE leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MSLE?
▼

For Satellos Bioscience Inc. (MSLE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #337 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.34 (-1.00%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.5% Base Target
$14 Bull$6 Base$5 Bear
📬 FREE MSLE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MSLE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY MSLE SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$7.04-0.6% Next Q
Q2 (-2Q)
51
Grade C-$7.00-1.7% Next Q
Q3 (-1Q)
49
Grade D$6.88-7% Next Q
Current
46
Grade D$6.40-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MSLE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MSLE currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.16) and Max Pain ($6.72) forces dealer call-delta covering toward $14.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MSLE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MSLE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (MSLE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for MSLE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MSLE)

  • ✓Walkthrough of MSLE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MSLE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.44%🛡️ HOLDING TREND SUPPORT
2026-11-03O $6.81H $6.81L $6.40C $6.40VOL 30.8K
RES: $10.28SUP: $6.10SMA50: $8.16SMA200: $8.47
$11.07$9.54$8.02$6.49$4.97RES $10.28SUP $6.10$6.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MSLE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MSLE Butterfly Map → + Track MSLE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MSLE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MSLE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MSLE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MSLE)

Health Care Rank #337 of 1015 ⚔️ RNA vs MSLE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MSLE vs. RNA, MENS, DERM, NBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Satellos Bioscience Inc. (MSLE) ranks #337 by composite RQD confidence (46/100, grade D) and #610 by equity capitalization ($142.2M). Within this direct 5-issuer industry benchmark cohort, MSLE leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. MSLE currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MSLE ACTIVE
Satellos Bioscience Inc.
D 46/100 — — — -4.48% $142.2M Benchmark Subject
RNA
Atrium Therapeutics Inc.
D 44/100 — — — +3.39% $141.5M /rna-vs-msle →
MENS
Jyong Biotech Ltd.
E 33/100 — — -28.8% -0.53% $142.9M /mens-vs-msle →
DERM
Journey Medical Corporation
E 16/100 — 65.8% -19.5% -7.35% $145.9M /derm-vs-msle →
NBP
NovaBridge Biosciences
E 34/100 — — -35.0% -10.46% $137.9M /nbp-vs-msle →

2. MSLE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Satellos Bioscience Inc. (MSLE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $142.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MSLE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MSLE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Satellos Bioscience Inc. (NASDAQ: MSLE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $6.40 (-4.48% 1D, market cap $142.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MSLE ranks #337 in composite RQD confidence.

How does MSLE compare to RNA and MENS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MSLE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNA (Atrium Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, MSLE leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MSLE?

For Satellos Bioscience Inc. (MSLE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #337 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MSLE trading relative to its 50-day, 200-day, and 52-week technical levels?

MSLE last traded at $6.40 (-4.48% on volume of 3,118 shares), positioning the stock -21.57% below its 50-day simple moving average ($8.16) and -24.44% below its 200-day simple moving average ($8.47). Across its 52-week range of $5.30 to $13.40, MSLE sits at the 13.6% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.60 to $7.20).

Direct Sub-Reports: MSLE RQD Cockpit MSLE 12M Forecast MSLE Earnings & Move MSLE Dividends & DRIP MSLE Insiders & 13F MSLE Whale Options MSLE Profit Sankey MSLE News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

MSLE — Satellos Bioscience Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Satellos Bioscience Inc. (MSLE) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $6.40 (-4.48% 1D, market capitalization $142.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Satellos Bioscience Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile reports a market capitalization of $0.1B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $5.30 – $13.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is NONE, with no upstream or downstream links and no sector-correlation entries. The graph is therefore empty for MSLE, and second-order ripple analysis cannot be performed from the source data. A prospective investor should note that no supply-chain dependencies, customer concentration, or sector correlations are documented here.

  • Key Question #1: Can MSLE sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $13.40 52-week high?
  • Key Question #3: How sensitive is MSLE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MSLE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Satellos Bioscience Inc. (MSLE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MSLE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MSLE Bull vs. Bear Conversation Board — What's Your Call at $6.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MSLE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MSLE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $8.24 (+23.0%)
📌 Pinned Debate

Moderate Buy consensus reported by MarketBeat, with Harvard and Stanford scientists advising on tissue repair.

The street is overcomplicating Satellos Bioscience Inc. (MSLE). Moderate Buy consensus reported by MarketBeat, with Harvard and Stanford scientists advising on tissue repair.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $7.24.

CapAlloc_Nerd 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $5.16 (-23.0%)
Spot @ $6.70

Zacks Research cut its rating to Strong Sell, and the RQD rating shows 0% ROIC and 0% FCF yield.

Careful chasing MSLE at $6.70. Zacks Research cut its rating to Strong Sell, and the RQD rating shows 0% ROIC and 0% FCF yield.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.16 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%